By writer to baytownsun.com
CAMBRIDGE, Mass., Oct. 9, 2020 /PRNewswire/ — Akebia Therapeutics®, Inc. (Nasdaq: AKBA) right now introduced that it’s going to current knowledge from its world Section three applications of vadadustat for the therapy of anemia as a result of continual kidney illness (CKD) in grownup sufferers on dialysis (INNO2VATE) and never on dialysis (PRO2TECT) at American Society of Nephrology Kidney Week 2020 Reimagined (ASN Kidney Week), which is going down nearly October 22 – 25, 2020. Vadadustat is Akebia’s investigational oral hypoxia-inducible issue prolyl hydroxylase inhibitor (HIF-PHI) in growth for the therapy of anemia as a result of CKD.
Accepted vadadustat and different abstracts from Akebia at the moment are obtainable on-line on the ASN Kidney Week summary portal: https://www.asn-online.org/education/kidneyweek/2020/program-search-abstract.aspx.
Outcomes from Akebia’s world Section three INNO2VATE program might be introduced by Kai-Uwe Eckardt, M.D., Professor of Drugs and Head of the Division of Nephrology and Inside Intensive Care Drugs on the Charité in Berlin, Germany, and Co-Chair of the impartial Govt Steering Committee for INNO2VATE and PRO2TECT, throughout the “Breakthroughs in Anemia and Iron Administration” session. The presentation, titled ” Global Phase 3 Clinical Trials of Vadadustat vs. Darbepoetin Alfa for Treatment of Anemia in Patients with Dialysis-Dependent CKD ” (Summary TH-OR01), is scheduled for Thursday, October 22, at 5:00 p.m. ET. In Could, Akebia reported constructive top-line outcomes from INNO2VATE demonstrating that vadadustat achieved this system’s major and key secondary efficacy endpoints and likewise achieved the first security endpoint.
Outcomes from Akebia’s world Section three PRO2TECT program might be introduced by Glenn Chertow, M.D., M.P.H., Professor of Drugs, Chief, Division of Nephrology at Stanford College, and Co-Chair of the impartial Govt Steering Committee for PRO2TECT and INNO2VATE, throughout the “Excessive-Impression Medical Trials” late-breaker session. The presentation, titled “World Section three Medical Trials of Vadadustat vs Darbepoetin Alfa for Remedy of Anemia in Sufferers with Non–Dialysis-Dependent Power Kidney Illness” (Summary FR-OR54), is scheduled for Friday, October 23 between 10:30 a.m. ET – 12:30 p.m. ET. In September, Akebia reported top-line outcomes from PRO2TECT demonstrating that whereas vadadustat achieved this system’s major and key secondary efficacy endpoints, it didn’t meet its major security endpoint.
“We’ve got an incredible set of knowledge to current on the upcoming ASN medical assembly together with, medical knowledge from our Section three INNO2VATE program, which continues to strengthen our confidence in a simple path towards vadadustat’s approval in dialysis. We beforehand introduced that this was a constructive research and we’re excited to current the info at ASN,” stated John P. Butler, President and CEO of Akebia Therapeutics. “We’re additionally very happy that our summary for our Section three PRO2TECT program in non-dialysis was chosen as a late-breaking oral presentation.”
A number of extra abstracts have been accepted for presentation at ASN Kidney Week.
Investor Briefing Webcast Akebia administration will host an investor briefing webcast with Dr. Glenn Chertow on October 23, 2020 at 4:10 p.m. ET to overview highlights of the Section three vadadustat knowledge displays from ASN Kidney Week. To entry Akebia’s investor briefing webcast and the accompanying slides please log into the Traders part of the Firm’s web site at https://ir.akebia.com and proceed to the occasions and displays web page at https://ir.akebia.com/events-and-presentations. Please connect with the Firm’s web site at the very least 10 minutes previous to the web occasion to make sure ample time for any software program obtain that could be required to view the webcast. After the webcast concludes, a replay of the occasion might be obtainable at that very same location till October 29, 2020.
About Vadadustat Vadadustat is an oral hypoxia-inducible issue prolyl hydroxylase (HIF-PH) inhibitor designed to imitate the physiologic impact of altitude on oxygen availability. At larger altitudes, the physique responds to decrease oxygen availability with stabilization of hypoxia-inducible issue, which may result in elevated crimson blood cell manufacturing and improved oxygen supply to tissues. Vadadustat is in world Section three growth for the therapy of anemia as a result of CKD and isn’t permitted by the U.S. Meals and Drug Administration (FDA) or any regulatory authority except Japan’s Ministry of Well being, Labour and Welfare (MHLW). In Japan, vadadustat is permitted as a therapy for anemia as a result of CKD in each dialysis-dependent and non-dialysis dependent grownup sufferers.
About Akebia Therapeutics Akebia Therapeutics, Inc. is a completely built-in biopharmaceutical firm with the aim to higher the lives of individuals impacted by kidney illness. The corporate was based in 2007 and is headquartered in Cambridge, Massachusetts.
Ahead-Trying Statements Statements on this press launch relating to Akebia’s technique, plans, prospects, expectations, beliefs, intentions and targets are forward-looking statements inside the which means of the U.S. Non-public Securities Litigation Reform Act of 1995, as amended, together with however not restricted to statements relating to Akebia’s confidence relating to its path towards vadadustat’s approval in dialysis. The phrases “confidence,” “easy path towards” and comparable references are supposed to determine forward-looking statements, though not all forward-looking statements comprise these figuring out phrases. Every forward-looking assertion is topic to dangers and uncertainties that would trigger precise outcomes to vary materially from these expressed or implied in such assertion, together with the timing and content material of recommendation given and selections made by well being authorities, together with advertising and marketing approval and labeling selections; the potential direct or oblique affect of the COVID-19 pandemic on our enterprise, operations, and the markets and communities wherein we and our companions, collaborators, distributors and clients function; manufacturing and high quality dangers; dangers related to administration and key personnel modifications and transitional durations; the precise funding required to proceed to commercialize our industrial product, develop and commercialize vadadustat and function the Firm; early termination of any of Akebia’s collaborations; Akebia’s and its collaborators’ potential to fulfill their obligations beneath Akebia’s collaboration agreements; the scope, timing, and end result of any authorized, regulatory and administrative proceedings; modifications within the financial and monetary situations of the companies of Akebia and its companions; and Akebia’s potential to acquire, preserve and implement patent and different mental property safety for our industrial product, vadadustat and every other product candidates. Different dangers and uncertainties embody these recognized beneath the heading “Threat Components” in Akebia’s Quarterly Report on Kind 10-Q for the quarter ended June 30, 2020 and different filings that Akebia could make with the U.S. Securities and Change Fee sooner or later. These forward-looking statements (besides as in any other case famous) converse solely as of the date of this press launch, and Akebia doesn’t undertake, and particularly disclaims, any obligation to replace any forward-looking statements contained on this press launch.
Akebia Therapeutics Kristen Ok. Sheppard, Esq. firstname.lastname@example.org
View unique content material to obtain multimedia: http://www.prnewswire.com/news-releases/akebia-to-present-global-phase-3-vadadustat-data-at-american-society-of-nephrology-kidney-week-2020-reimagined-301149677.html
SOURCE Akebia Therapeutics
Copyright © 2020 PR Newswire Affiliation LLC. All Rights Reserved.
— to baytownsun.com